Stiffening Cancer Cells Enhances CAR T-Cell Therapy Efficacy in Melanoma Study

Recent research indicates that increasing the stiffness of cancer cells can significantly boost the effectiveness of CAR T-cell immunotherapy. Scientists discovered that cancer cells are typically softer than healthy cells due to higher cholesterol content in their membranes, which may help them evade immune detection. In a study involving mice with melanoma, researchers injected methyl β-cyclodextrin (meβCD) into tumors to reduce membrane cholesterol and stiffen the cells. This treatment was combined with engineered T-cells and IL-15 infusions. The results were striking: while all control mice died from tumor growth, five out of twelve treated mice saw their tumors completely disappear. The stiffened cells allowed T-cells to latch on more strongly and deliver toxic molecules like perforin more efficiently. Although challenges remain in translating mouse results to humans due to immune system differences, experts are optimistic because cancer cell softness is consistent across species. The research team is now developing single-injection drugs with similar effects and plans to test the approach on various tumor types. This physical approach to tackling cancer represents a promising new direction for improving survival rates in immunotherapy treatments.